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ABSTRACT
Background Breast cancer (BC) progression to metastatic 
disease is the leading cause of death in women worldwide. 
Metastasis is driven by cancer stem cells (CSCs) and 
signals from their microenvironment. Interleukin (IL) 30 
promotes BC progression, and its expression correlates 
with disease recurrence and mortality. Whether it acts by 
regulating BCSCs is unknown and could have significant 
therapeutic implications.
Methods Human (h) and murine (m) BCSCs were tested 
for their production of and response to IL30 by using flow 
cytometry, confocal microscopy, proliferation and sphere- 
formation assays, and PCR array. Immunocompetent mice 
were used to investigate the role of BCSC- derived IL30 on 
tumor development and host outcome. TCGA PanCancer 
and Oncomine databases provided gene expression 
data from 1084 and 75 hBC samples, respectively, and 
immunostaining unveiled the BCSC microenvironment.
Results hBCSCs constitutively expressed IL30 as a 
membrane- anchored glycoprotein. Blocking IL30 hindered 
their proliferation and self- renewal efficiency, which 
were boosted by IL30 overexpression. IL30 regulation of 
immunity gene expression in human and murine BCSCs 
shared a significant induction of IL23 and CXCL10. Both 
immunoregulatory mediators stimulated BCSC proliferation 
and self- renewal, while their selective blockade 
dramatically hindered IL30- dependent BCSC proliferation 
and mammosphere formation. Orthotopic implantation 
of IL30- overexpressing mBCSCs, in syngeneic mice, 
gave rise to poorly differentiated and highly proliferating 
MYC+KLF4+LAG3+ tumors, which expressed CXCL10 
and IL23, and were infiltrated by myeloid- derived cells, 
Foxp3+ T regulatory cells and NKp46+RORγt+ type 3 
innate lymphoid cells, resulting in increased metastasis 
and reduced survival. In tumor tissues from patients with 
BC, expression of IL30 overlapped with that of CXCL10 
and IL23, and ranked beyond the 95th percentile in a 
Triple- Negative enriched BC collection from the Oncomine 
Platform. CIBERSORTx highlighted a defective dendritic 
cell, CD4+ T and γδ T lymphocyte content and a prominent 
LAG3 expression in IL30high versus IL30low human BC 
samples from the TCGA PanCancer collection.
Conclusions Constitutive expression of membrane- bound 
IL30 regulates BCSC viability by juxtacrine signals and via 
second- level mediators, mainly CXCL10 and IL23. Their 
autocrine loops mediate much of the CSC growth factor 
activity of IL30, while their paracrine effect contributes to 
IL30 shaping of immune contexture. IL30- related immune 
subversion, which also emerged from computational 
analyses, strongly suggests that targeting IL30 can restrain 
the BCSC compartment and counteract BC progression.
BACKGROUND
Breast cancer (BC) is the leading cancer 
killer among women worldwide.1 Mortality is 
due to metastatic disease for which there is no 
effective cure. Metastasization is driven by a 
small population of cancer stem cells (CSCs), 
which are prevalent in BCs with a worse prog-
nosis,2 and may contribute to their propensity 
for metastasis and chemotherapy resistance.3 
Signals regulating CSC entry or exit from the 
steady- state condition are fundamental in 
shaping BC behavior and patient outcome.3 
The immunoregulatory molecule, interleukin 
(IL) 30, has been found in murine (m) pros-
tate cancer (PC) stem- like cells (SLCs) and 
has revealed autocrine and paracrine effects 
in the PC stem cell niche microenvironment 
and a critical role in PC onset and progres-
sion.4 5 Targeting IL30 signaling in PC- SLCs 
and host environment has proven to coun-
teract PC growth and improve host survival.5
Discovered in 2002 and identified as the 
p28 subunit of the heterodimeric cytokine 
IL27,6 which has demonstrated antitumor 
effects,7–9 IL30 can act as a self- standing 
cytokine, endowed with its own functional 
properties,10–12 that signals via IL6 Receptor 
Subunit Alpha (IL6R) by recruiting a gp130 
homodimer.13
In PC and BC, IL30 is produced by cancer 
and leukocytes infiltrating the tumor or 
draining lymph nodes (LNs), particularly in 
the high grade and stage of disease.14 15 In 
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STAT3 signaling, a broader program of proliferation, 
invasive migration and inflammatory milieu and induces 
cancer cell expression of MYC and SHH, which are funda-
mental in the maintenance of a putative CSC compart-
ment.16 17 In patients with BC, high levels of IL30, in 
tumor and draining LNs, have been associated with recur-
rence and correlated with mortality at multivariate anal-
yses.15 The lack of IL30 in the tumor microenvironment 
has proved effective in inhibiting the growth and progres-
sion of Triple- Negative (TN) BC,18 the molecular subtype 
with the highest CSC content.19
In the present study, we provide evidence that human 
and murine BCSCs are both the source and target of 
IL30, and identify the second- level mediators induced by 
IL30 in BCSCs and their impact on CSC behavior, immu-
nological context, and host outcome.
MATERIALS AND METHODS
Cell cultures and MTT assay
Human (h) BCSCs, BCSC- 608 and BCSC- 105, were 
generated and provided by Professor G Stassi (Univer-
sity of Palermo, Italy), who characterized them as CSCs, 
which grew in spheres and reproduced, in immunocom-
promised host, the tumor of origin.20 Both cell lines 
were authenticated by surface staining for characteristic 
markers, as described.20
Murine (m) BCSCs, Py230 cells, were derived from a 
mammary tumor spontaneously arisen in a MMTV- PyMT 
(mouse mammary tumor virus promoter driven Polyoma 
middle T- antigen) transgenic female C57BL/6J mouse, 
and were identified as CSCs, which grew in spheres and 
reproduced the parental tumor, when implanted as a 
single cell into syngeneic host.21 mBCSCs were purchased 
from ATCC (ATCC Cat# CRL- 3279, RRID:CVCL_AQ08) 
and authenticated by Short- Tandem Repeat profiling.
Murine (m) BC cells, E0771 mammary adenocarci-
noma cell line (RRID:CVCL_GR23), were derived from 
a spontaneous mammary tumor developed in a female 
C57BL/6J mouse,22 and were characterized as Triple- 
Negative and Basal- like.23 E0771 cells were purchased 
from CH3BioSystems (Amherst, NY, USA) and authenti-
cated by Short- Tandem Repeat profiling.
All cell lines were passaged for fewer than 6 months 
after resuscitation and were confirmed mycoplasma- free 
by PCR analysis.
Cell proliferation was assessed using the CellTiter 96 
AQueous One Solution Cell Proliferation Assay (#G3582; 
Promega, Madison, WI, USA), according to manufactur-
er’s instructions, as described in the online supplemental 
materials and methods.
Flow cytometry
To assess phenotype markers, BCSCs were harvested and 
mechanically dissociated into a single cell suspension. 
The cells were pelleted, suspended in PBS and incu-
bated, for 30 min at 4°C, with the antibodies (Abs) listed 
in online supplemental table S1, at a concentration of 
0.25 µg/100 µl. Acquisition was performed using a BD 
Scientific Canto II Flow Cytometer (RRID:SCR_018056) 
and the data were analyzed using FlowJo software (FlowJo, 
RRID:SCR_008520). Dead cells were excluded by 7AAD 
staining. All experiments were performed in triplicate.
Transfection with IL27p28 (IL30) expressing vector
Creation of IL30 lentiviral expression vector, and its trans-
fection into Py230 cells, were performed as described in 
online supplemental materials and methods. Expression 
of IL30 was confirmed by real- time RT- PCR, Western blot-
ting (WB) and ELISA.
For transient overexpression of human IL30 in BCSC- 
608, we used the IL27 Human Tagged ORF Clone 
(#RC209337L1; Origene, Rockville, MD, USA), which was 
transfected in BCSC- 608 cells using Lipofectamine 3000 
Reagent (#L3000001; Thermo Fisher Scientific, Waltham, 
MA, USA). Overexpression of IL30 was confirmed by real- 
time RT- PCR and WB.
IL30 gene silencing
IL30 silencing in hBCSCs was achieved by using the 
Human shRNA Plasmid Kit (#TR303941; Origene, Rock-
ville, MD, USA). Non- effective scrambled (Scr) shRNA 
was used as control. Downregulation of IL30 expression 
was confirmed by real- time RT- PCR and WB.
PCR array and real-time RT-PCR
PCR array and real- time RT- PCR were performed, as 
described in online supplemental materials and methods. 
Expression of human and murine inflammation and 
immunity genes, listed in online supplemental tables 
S2,S3, was investigated in IL30 overexpressing or silenced 
human and murine BCSCs.
Enzyme-linked immunosorbent assay
Quantitation of IL30, CXCL10, IL23, CXCL1 and CSF2, 
in the supernatant derived from murine or human BCSCs, 
was carried out as described in online supplemental mate-
rials and methods.
Western blotting
Western blot (WB) was performed to assess IL30 overex-
pression in mBCSCs and IL30 overexpression or silencing 
in hBCSCs, as described in the online supplemental mate-
rials and methods.
Sphere formation assay
The sphere- formation efficiency, and the associated self- 
renewal ability, of murine and human BCSC cells was 
assessed by using the Extreme Limiting Dilution Anal-
ysis (ELDA, RRID:SCR_018933),24 as described in online 
supplemental materials and methods.
Mouse studies
The tumorigenicity of mBCSCs was assessed, by limiting 
dilution analysis, by Bao and coworkers.21 Experi-
mental conditions for tumor growth were determined 
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(RRID:IMSR_JAX:000664, purchased from Envigo, India-
napolis, IN, USA), of different dilutions of mBCSCs, and 
after the assessment of the tumor microenvironment and 
latency times, as reported in online supplemental mate-
rials and methods and figure S1.
Finally, three groups of forty- five 8 week old mice were 
subcutaneously injected with 1×104 wild- type (CTRL) 
mBCSCs, Empty Vector (EV) or IL30 lentiviral- DNA 
(IL30LV- DNA) transfected mBCSCs, also referred to as 
IL30mBCSCs. Based on tumor growth and progression 
rate, 15 mice from each group were euthanized at key 
time points (3 mice per point) for histopathological and 
molecular analyses. The remaining 30 mice per group 
were kept until tumors reached 1000 mm3 or evidence 
of suffering was observed. Autopsy and histopathological 
examinations of the different organs (liver, lungs and 
spleen) were performed. With an overall sample size of 
30 mice per group, a one- sided log- rank test detected a 
difference of 30% in tumor growth between two groups, 
with a 90% power, at a 0.05 significance level (G*Power, 
RRID:SCR_013726).25
For the experimental metastasis assay, three groups of 30 
C57BL/6J mice were injected, into the tail vein, with 5×104 
mBCSCs, EVmBCSCs or IL30mBCSCs. Mice were sacri-
ficed 40 days after tumor cell injection and the lungs were 
analyzed for the presence of metastases. Briefly, formalin- 
fixed lungs were cut into transverse slices, embedded in 
paraffin and subjected to semiserial 3 µm sections. H&E- 
stained sections were histopathologically analysed, for 
the presence of spontaneous or experimental metastasis, 
under a light microscope (DMLB light microscope; Leica 
Microsystems, Wetzlar, Germany).
Patients and samples
Thirty- two tumor samples classified as Triple- Negative 
BCs, according to the St. Gallen International Expert 
Consensus in 2011, were obtained from the Anatomic 
Pathology Department of the “S.S. Annunziata Hospital”, 
Chieti, Italy, after written informed consent from patients. 
Patients’ clinicopathological characteristics are shown in 
online supplemental table S4. This sample size allows to 
detect, with an 80% power, a difference of 10% in the 
number of CXCL10 (or IL23) positive cells/total number 
of CD133+IL30+ cells per field, at a 0.05 significance 
level.26
Histopathology, immunohistochemistry and confocal 
microscopy
Histology, immunohistochemistry and confocal micros-
copy were performed as described in online supple-
mental materials and methods, using the antibodies listed 
in online supplemental table S5.
Proliferation index, microvessel and cell counts were 
assessed by light microscopy (DMLB light microscope; 
Leica Microsystems), at ×400 in an 85,431.59 µm2 field, 
on single or triple (CD133/IL30/CXCL10 or IL23) 
immunostained sections, using QWin image analysis 
software (Leica QWin, RRID:SCR_018940). Six to eight 
high- power fields were analyzed for each section and 
three sections per sample were evaluated. Results were 
expressed as mean±SD of positive cells per field (F4/80, 
CD11b, Foxp3, CD3, Ly- 6G, CD4, CD8, NKp46/RORγt), 
or mean percentage ±SD of positive cells/number 
of total cells per field (PCNA, MYC, KLF4), or mean 
percentage ±SD of CXCL10 or IL23 positive cells/total 
number of CD133+IL30+ cells per field. Microvessels 
were identified as small tubes or circles marked by CD31 
Abs and results were expressed as mean±SD of positive 
vessels/field. Each slide was analyzed by two independent 
investigators, in a blind fashion, and there was an almost 
perfect agreement (kappa value=0.82) between their 
evaluations.
Bioinformatic analyses
For bioinformatic analyses (cBioPortal, 
RRID:SCR_014555), gene expression data from the “Breast 
Invasive Carcinoma TCGA PanCancer collection” dataset,27 
which includes 1084 BC cases, and from Waddell’s data-
base, which predominantly contains TNBCs (26 out 
of 75 cases), were downloaded from the cBioportal for 
Cancer Genomics database (https://www. cbioportal. org; 
cBioPortal, RRID:SCR_014555) and Oncomine website 
(https://www. oncomine. org; Oncomine Research Plat-
form, RRID:SCR_007834), respectively. For each sample, 
the Z- scores of gene expression levels were calculated, 
compared with the mean of all samples in the study, 
and all samples with a Z- score ≥2 were considered over-
expressing. Subsequently, we selected only the cases for 
which information regarding the tumor subtype was 
available, and assessed the association between gene 
expression and BC subtypes using Fisher’s exact test. The 
correlation between gene expressions was assessed using 
Spearman’s rank correlation coefficient (ρ). The Cancer 
Outlier Profile Analysis (COPA) on Waddell’s database 
was performed using the data analysis tool included in 
the Oncomine Platform.
To estimate the tumor- infiltrating immune cell content 
in BC samples, transcripts per million–normalised RNA- 
seq data of the “Breast Invasive Carcinoma TCGA PanCancer 
collection” were downloaded from http:// firebrowse. org 
and analyzed using CIBERSORTx,28 a computational 
framework, which accurately infers cell type abundance 
from the RNA profiles of tissue samples, using specific 
gene signatures. LM22 was used as signature matrix that 
contains 547 genes, which distinguish 22 human hema-
topoietic cell phenotypes,29 and batch correction option 
was enabled to remove technical differences between 
the signature matrix and RNA- seq data. Results were 
converted in .xlsx file format, and between- group differ-
ences were assessed by Student’s t- test.
All statistical tests were evaluated at an α level of 0.05.
Statistical analysis
For in vitro and in vivo studies, between- group differ-
ences were assessed by Student’s t- test, or ANOVA, 
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in sphere- forming potential were evaluated by ELDA.24 
Survival curves were constructed using the Kaplan- Meier 
method and survival differences were analyzed by the log- 
rank test. All statistical tests were evaluated at an α level 
of 0.05 using Stata V.13 (StataCorp, College Station, TX, 
USA; RRID:SCR_012763).
RESULTS
IL30 promotes the viability and mammosphere forming ability 
of BCSCs
To explore IL30’s impact on human (h) and murine 
(m) BCSC behavior, we first investigated whether they 
expressed the IL30 receptor (R) and produced the 
cytokine.
hBCSCs, referred to as BCSC- 608 and BCSC- 105, were 
isolated from invasive ductal adenocarcinomas and 
are endowed with the functional properties of CSCs.20 
mBCSCs, Py230, were isolated from a spontaneously 
arising tumor in MMTV- PyMY transgenic mouse and 
identified as multipotent mammary CSCs.21 To exclude 
differentiated cells, human and murine BCSCs were 
phenotypically validated by flow cytometry. hBCSCs 
displayed a CD24+CD29+CD117+CD133+ phenotype and 
mBCSCs were characterized by a CD24+CD44+CD49f+ 
phenotype (online supplemental figure S2). Both human 
and murine BCSCs expressed the two IL30R chains,11 14 
IL6Rα (CD126) and gp130 (CD130) (figure 1A).
IL30 was undetectable, by ELISA, in the supernatant of 
hBCSCs. Unlike its murine counterpart, which is secreted 
as a soluble mediator, hIL30 (IL27p28 subunit, or IL27α) 
is not released, unless it heterodimerizes with a β-subunit 
(EBI3 or Cytokine- Like Factor 1) or a molecular mecha-
nism, which affects protein folding, determines protein 
secretion.30
However, analysis of its peptide sequence, with 
PSIPRED (Department of Computer Science, University 
College of London; figure 1B,C), revealed the presence 
of a stretch of 16 residues toward the carboxy- terminus of 
the protein, made up of 75% hydrophobic amino acids, 
which is predictive of a single- pass type I transmembrane 
helix. Flow cytometry (figure 1D), WB analyses (which 
discriminated the cytoplasmic and plasma membrane 
protein fractions; see CTRL cells in figure 1E,F) and 
confocal microscopy (which showed IL30 co- localization 
with Na+K+- ATPase31 (figure 1G,H), demonstrated that 
IL30 localized in the plasma membrane of hBCSCs.
IL30 overexpression, via gene transfection, in both 
BCSC- 608 and BCSC- 105 (figure 1I,J), confirmed the 
localization of IL30 in the cell membrane (figure 1E,F) 
and significantly increased BCSC proliferation (ANOVA: 
p=0.03 and p=0.001, respectively; figure 1K,L). By 
contrast, the blockade of constitutively produced IL30, 
by specific neutralizing Abs, significantly decreased the 
proliferation (Student’s t- test, p=0.0006) (figure 1M,N) 
and mammosphere- forming capability of both hBCSCs 
(χ2 test, p<0.05) (figure 1O, P and Q), an effect that 
could not be ascribed to the blockade of IL27, since IL30 
was undetectable in the supernatants.
Considering that IL30 was neither produced nor 
released by mBCSCs, as assessed by ELISA, we trans-
fected them with the IL30 gene and generated a 
clone, namely IL30mBCSC (figure 1R,S), that released 
20.25 ng/mL of IL30. Both IL30mBCSCs, and wild- type 
mBCSCs treated with rIL30 (50 ng/mL), showed a higher 
proliferation rate (ANOVA: p<0.0001; Tukey HSD test, 
p<0.01) (figure 1T) and mammosphere- forming effi-
ciency (χ2 test, p<0.05) (figure 1U) when compared with 
EVmBCSCs and mBCSCs (CTRL), respectively. The addi-
tion of neutralizing anti- IL30 Abs to the culture medium 
of IL30- overexpressing mBCSCs consistently decreased 
both their proliferation (ANOVA: p<0.0001; Tukey HSD 
test, p<0.01) and mammosphere formation efficiency (χ2 
test, p<0.05) (figure 1T,U).
Human “membrane-bound” and murine “secreted” IL30 
shapes immunity gene expression profiles of BCSCs that 
share a strong upregulation of CXCL10 and IL23
To assess whether IL30 affects BCSC−host immunity 
interactions, we first analyzed the inflammation and 
immunity gene expression profile of BCSC- 608, which 
among hBCSCs had the highest level of constitutive 
IL30 expression (figure 1D), after IL30 gene silencing 
and overexpression. Changes in the expression level of 
membrane- bound IL30, obtained by IL30 gene silencing 
and overexpression in hBCSC- 608, were proved at the 
transcriptional (figure 1I) and protein level by WB 
(figures 1E and 2A), flow cytometry (figure 2B) and 
confocal analyses (figure 2C, D and E).
IL30- overproduction by hBCSCs stimulated their 
expression of cytokines and immune regulatory media-
tors (figure 2F), such as IL1B (2.87 times), TNFA (3.15 
times) and, especially, of CSF2 (67.41 times) and IL23A 
(36.12 times), whereas the expression of HLA- A (−2.88 
times), IL10 (−3.11 times), IL12A (−2.47 times) and IL15 
(−3.57 times) were inhibited. hIL30 overproduction by 
hBCSCs also promoted the expression of genes coding 
for chemokines, such as CCL4 (3.69 times), CXCL1 (15.83 
times), CXCL8 (2.86 times) and CXCL10 (5.57 times). By 
contrast, hIL30 silencing downregulated CXCL10 (−3.12 
times), PTGS2 (−3.14 times) and IL1B (−241.7 times), 
together with chemokines and chemokine receptors, 
CCL5 (−3.34 times), CCL28 (−2.15 times), CXCL11 (−4.83 
times), CCR2 (−2.21 times), CXCR2 (−3.01 times) and 
CXCR4 (−3.2 times). Expression of NOS2 (−2.15 times), 
PDL2 (−2.76 times) and, primarily, STAT3 (−21.41 times) 
was also downregulated in hBCSCs by hIL30 silencing.
Assessment of the most highly upregulated media-
tors, specifically CSF2 and CXCL1, in the supernatant of 
IL30- overexpressing BCSC- 608 confirmed their substan-
tial increase at the protein level (CSF2: 20.57±0.56 pg/
mL in IL30- over, versus 8.62±1.73 pg/mL in EV, and 
8.46±0.70 pg/mL in CTRL cells. ANOVA: p<0.0001; Tukey 
HSD test: p<0.01 versus both EV and CTRL cells) (CXCL1: 
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Figure 1 Expression of IL30 receptor in breast cancer stem cells (BCSCs) and their response to IL30 treatment. (A) 
Cytofluorimetric analyses of gp130 (CD130) and IL6Rα (CD126) expression in human and murine BCSCs. Red lines: isotype 
control. Blue lines: specific Abs. Experiments were performed in triplicate. (B) Amino acid sequence and (C) tertiary structure 
of hIL30 protein. The extracellular portion is shown in orange, the signal peptide is shown in pink, the transmembrane helix 
is shown in gray (starting with the serine residue at position 209 and ending with the leucine residue at position 224) and the 
cytoplasmic portion is shown in white. (D) Cytofluorimetric analyses of IL30 expression in hBCSCs. The BCSC- 608 cells showed 
a mean fluorescence intensity (MFI) ratio of 8.5 whereas BCSC- 105 cells showed a MFI ratio of 2.3. The MFI was obtained 
calculating the ratio between the fluorescence of the samples and their isotype controls. Red lines: isotype control. Blue lines: 
anti- IL30 Abs. Experiments were performed in triplicate. (E, F) Western blot analyses of IL30 protein expression in the cytosolic 
and plasma membrane fractions of wild- type (CTRL), EV and IL30 gene transfected (IL30- over) BCSC- 608 (E) and BCSC- 105 
(F). (G, H) Confocal microscopy analyses of BCSC- 608 (G) and BCSC- 105 (H) highlights in green the plasma membrane 
expression of IL30 that co- localizes with the red- stained Na+K+- ATPase, and in blue the nuclei, stained with 4′-6‐diamidino‐2‐
phenylindole (DAPI). Magnification: ×400. Scale bars: 6 µm. (I, J) Relative expression ±SD of IL30 mRNA in wild- type (CTRL), EV 
and IL30 gene transfected (IL30- over) BCSC- 608 (I) and BCSC- 105 (J). ANOVA, p<0.0001. *p<0.01, Tukey HSD test compared 
with CTRL and EV- hBCSCs. (K, L) MTT assay of IL30 gene transfected (IL30- over) BCSC- 608 (K) and BCSC- 105 (L) versus EV- 
transfected and CTRL cells. ANOVA, p<0.05. *p<0.05, Tukey HSD test compared with CTRL and EVhBCSCs. (M, N) MTT assay 
of BCSC- 608 (M) and BCSC- 105 (N), after 48 hours of treatment with anti- IL30Abs (BCSC- 608: 0.5 µg/mL and BCSC- 105: 5 µg/
mL). *Student’s t- test: p<0.05. (O) Sphere- forming assay, evaluated by ELDA, of BCSC- 608 after 5 and 10 days of treatment 
with anti- IL30Abs (0.5 µg/mL). *p=0.00489, χ2 test compared with untreated cells. **p=0.021, χ2 test compared with untreated 
cells. (P) BCSC- 608–derived spheres were dissociated, seeded at concentrations of 1 cell/well, and untreated (CTRL, pictures 
on the left) or treated with anti- IL30 Abs (0.5 µg/mL) (pictures on the right). Magnification: ×400. Scale bars: 100 µm. (Q) Sphere- 
forming assay, evaluated by ELDA, of BCSC- 105 after 5 and 10 days of treatment with anti- IL30Abs (0.5 µg/mL). *p=0.00374, χ2 
test compared with untreated cells. **p=0.012, χ2 test compared with untreated cells. (R) Relative expression ±SD of Il30 mRNA 
in Il30 gene transfected (IL30LV- DNA) mBCSCs, that is, IL30mBCSCs. ANOVA, p<0.0001. *p<0.01, Tukey HSD test compared 
with wild- type (CTRL) and EVmBCSCs. (S) Western blot analysis of IL30 protein expression in CTRL, EV and IL30mBCSCs 
(IL30LV- DNA). (T) MTT assay of mBCSCs after 48 hours of treatment with rIL30 (50 ng/mL), and of IL30mBCSCs (IL30LV- DNA) 
with and without anti- IL30 Abs. ANOVA, p<0.0001. *p<0.01, Tukey HSD Test versus CTRL, EV, IL30LV- DNA and IL30LV- DNA 
+ IL30 Abs. **p<0.01, Tukey HSD test versus CTRL, rIL30, EV and IL30LV- DNA + IL30 Abs. ***p<0.05, Tukey HSD test versus 
CTRL, rIL30, EV and IL30LV- DNA. (U) Sphere- forming assay, evaluated by ELDA, of mBCSCs after 15 days of culture with rIL30 
(50 ng/mL), and of IL30mBCSCs (IL30LV- DNA) with and without anti- IL30 Abs. *p<0.05, χ2 test versus CTRL, EV and IL30LV- 




















6 Sorrentino C, et al. J Immunother Cancer 2021;9:e002966. doi:10.1136/jitc-2021-002966
Open access 
Figure 2 IL30- dependent regulation of the immunity gene expression in breast cancer stem cells (BCSCs). (A) Western blot 
analyses of IL30 protein expression in wild- type (CTRL), IL30shScrRNA and IL30shRNA transfected BCSC- 608 cells. (B) 
Flow cytometric analysis of IL30 expression on the cell membrane of EV and IL30- over, ScrRNA and IL30shRNA transfected 
BCSC- 608 cells. Results from untransfected BCSC- 608 cells are comparable with those from EV and IL30shScrRNA 
transfected cells. (C–E) Confocal microscopy images of IL30 expression (green) that co- localizes with the red- stained 
Na+K+- ATPase in wild- type (CTRL) (C), IL30- silenced (shRNA) (D) and IL30- overexpressing (IL30- over) (E) BCSC- 608. DAPI: 
DNA- stained nuclei. Magnification: ×400. Scale bars: 6 µm. (F) Fold differences of mRNAs of human inflammation and 
immunity- related genes between IL30shRNA- transfected and ScrRNA- transfected BCSC- 608 (blue bars) and between IL30 
gene- transfected and EV- transfected BCSC- 608 (red bars). Results from ScrRNA- transfected and EV- transfected cells are 
comparable with those from untransfected wild- type cells. Pooled results±SD are from two experiments performed in duplicate. 
A significant threshold of 2- fold change in gene expression corresponded to p<0.001. (G) Fold differences of mRNAs of murine 
inflammation and immunity genes between Il30 gene- transfected and EV- transfected mBCSCs. Results from EV- transfected 
cells are comparable with those from untransfected wild- type cells. Pooled results±SD are from two experiments performed in 
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EV, and 3.33±1.40 pg/mL in CTRL cells. ANOVA: p=0.009; 
Tukey HSD test: p<0.05 versus both EV and CTRL cells).
To compare the response of hBCSCs to IL30 with that 
of its murine counterpart, which will be useful in vivo 
in the immunocompetent model, the immunity gene 
expression profile was also analysed in mBCSCs after 
rIL30 treatment (figure 2G).
In mBCSCs, rIL30 upregulated Stat1 (2.31 times), Bcl- 
2- like protein 1 (Bcl2l1) (2.69 times) and Myc (7.04 times), 
and boosted the expression of a set of genes coding for 
growth factors, such as Csf1 (2.93 times), Csf3 (4.04 times), 
Vegfa (6.50 times), Egf (2.21 times), Egfr (3.78 times) and 
inflammatory mediators, such as Il1a (6.94 times) and, 
especially, Il23a (12.68 times) and Ptgs2 (15.78 times), 
whereas Il15 and Irf1 were downregulated (−2.90 and 
−2.38 times, respectively).
Recombinant IL30 also stimulated mBCSC expression 
of chemokines and their receptors, such as Ccr9 (2.89 
times), Ccl20 (3.22 times), Cxcl2 (2.54 times), Cxcl12 (3.56 
times) and particularly Cxcl10 (27.47 times), along with 
expression of immune checkpoint molecules Cd274/Pd- l1 
(2.02 times), Lag3 (2.46 times) and Ox40 (3.33 times).
Comparative analysis of human and murine IL30- driven 
transcriptional profiles revealed a common and substan-
tial upregulation of CXCL10 and IL23A, which prompted 
us to assess their role in IL30- dependent regulation of 
BCSC viability.
CXCL10 and IL23 autocrine loops mediate IL30-dependent 
proliferation of BCSCs
IL30- induced upregulation of CXCL10 and IL23 in 
human and murine BCSCs, led us to investigate their 
production and functional consequences.
The treatment of mBCSC cells with rIL30 (50 ng/
mL, 48 hours) stimulated the production and release of 
CXCL10 (105.90±11.20 pg/mL versus 69.60±5.73 pg/
mL in untreated cells; Student’s t- test: p=0.02). At 
concentrations ranging from 30 to 150 ng/mL, CXCL10 
significantly increased the proliferation of both mBCSCs 
(ANOVA: p<0.0001; Tukey HSD test: p<0.05) (figure 3A) 
and mBC cell line E0771 (ANOVA: p<0.0001; Tukey HSD 
test: p<0.01) (figure 3B), a TN cell line isolated from a 
mammary tumor developed in a female mouse with the 
identical genetic background of mBCSCs. Both cell lines 
expressed the CXCL10 receptor, CXCR3 (figure 3C).
The increased proliferation of mBCSCs induced by 
rIL30 or the supernatant obtained from IL30mBCSCs 
(IL30sup) was significantly inhibited, although not abol-
ished, by the addition of anti- CXCL10 Abs (ANOVA: 
p<0.0001; Tukey HSD test: p<0.05) (figure 3D), which 
strongly suggests the existence of an autocrine loop trig-
gered by IL30- induced CXCL10.
Treatment of mBCSCs with rIL30 (50 ng/mL) also stimu-
lated the production and release of IL23 (75.10±13.71 pg/
mL versus 53.26±6.19 pg/mL in untreated cells; Student’s 
t- test p=0.04). However, although both mBCSCs and mBC 
cells expressed the IL12Rβ1 (online supplemental figure 
S3), neither cell lines expressed the IL23R (figure 3E),32 
which indicates that, at least in the mouse model, only 
paracrine effects can be expected by IL30- induced IL23.
CXCR3, specifically the isoforms CXCR3- A and 
CXCR3- B (figure 3F,G,H,I), and IL23R (figure 3J) were 
expressed by hBCSCs, and the treatment with rCXCL10 
or rIL23 (5–100 ng/mL) significantly increased both 
their proliferation (ANOVA: p<0.01) (figure 3K, L, M 
and N) and their mammosphere formation efficiency 
(rCXCL10 treated BCSC- 608, p<0.0001, χ2 test versus 
CTRL; rCXCL10 treated BCSC- 105, p=0.0029, χ2 test 
versus CTRL; rIL23 treated BCSC- 608, p<0.0001, χ2 test 
versus CTRL; rIL23 treated BCSC- 105, p=0.0044, χ2 test 
versus CTRL) (figure 3O, P, Q and R).
ELISA revealed that both BCSC- 608 and BCSC- 105 
constitutively released CXCL10 (23.86±1.31 pg/mL and 
4411.40±62.98 pg/mL, respectively), but not IL23.
IL30 overexpression by IL30 gene transfected BCSC- 608 
dramatically increased the production (figure 4A) and 
release of CXCL10 (IL30- over: 28.64±0.53 pg/mL, versus 
EV: 23.41±0.60 pg/mL, and CTRL cells: 23.86±1.31 pg/
mL; ANOVA: p=0.0006; Tukey HSD test: p<0.01 versus 
both EV and CTRL cells) and induced the production 
(figure 4B) and release of IL23 (IL30- over: 8.89±1.28 pg/
mL, versus EV and CTRL cells: 0.00 pg/mL).
IL30 overexpression by IL30 gene transfected BCSC- 
105 also increased the production (figure 4C) and 
release of CXCL10 (IL30- over: 4738.63±15.75 pg/
mL, versus EV: 4406.82±68.30 pg/mL, and CTRL cells: 
4411.40±62.98 pg/mL; ANOVA: p=0.0004; Tukey HSD 
test: p<0.01 versus both EV and CTRL), while IL23 was 
undetectable (online supplemental figure S4).
The addition of neutralizing anti- CXCL10 Abs (0.5–
1.0 µg/mL) or anti- IL23 Abs (0.5–1.0 µg/mL) to the 
culture medium of IL30- overexpressing BCSC- 608 signifi-
cantly (ANOVA: p<0.001) inhibited IL30- dependent cell 
proliferation (figure 4D,E). At a concentration of 0.5 µg/
mL, the anti- CXCL10 Abs reduced, but did not abolished, 
the proliferative effect induced by IL30 overexpression, 
and the combination with anti- IL23 Abs brought the 
proliferation back to CTRL levels. (figure 4F).
As observed in wild- type BCSC- 608 (figure 4D), neutral-
izing anti- CXCL10 Abs (0.5–1.0 µg/mL) decreased the 
proliferation of wild- type BCSC- 105, since they consti-
tutively released the chemokine, and significantly 
(ANOVA: p<0.0001) suppressed the proliferation of IL30- 
overexpressing BCSC- 105 (figure 4G), thus strengthening 
the role of the CXCL10- triggered autocrine loop in medi-
ating IL30- induced BCSC proliferation.
IL30 overproduction by BCSCs boosts tumor growth and 
reduces survival in association with tumor production of 
CXCL10 and IL23 and infiltration by MDC, Tregs and ILC3
The effect of IL30 overexpression by BCSCs on tumor 
onset and progression was investigated after orthotopic 
implantation of IL30mBCSCs and control clones (1×104 
cells) in syngeneic C57BL/6 female mice. Fifteen days 
after their implantation, IL30mBCSCs gave rise to tumors, 
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Figure 3 IL30- dependent regulation of breast cancer stem cell (BCSC) viability. (A) MTT assay of mBCSCs after 48 hours 
treatment with rCXCL10 at concentrations of 30, 50, 100 and 150 ng/mL. ANOVA: p=0.00001. *p<0.05, Tukey HSD test 
compared with 0 ng/mL. (B) MTT assay of mBC cells after 48 hours of treatment with rCXCL10 at concentrations of 30, 50, 
100 and 150 ng/mL. ANOVA: p=0.00006. *p<0.01, Tukey HSD test compared with 0 ng/mL. (C) Cytofluorimetric analyses 
of CXCR3 expression in mBCSCs and mBC cells. Red lines: isotype control. Blue lines: specific Abs. Experiments were 
performed in triplicate. (D) MTT assay of mBCSCs 48 hours after the treatment with rmIL30 (50 ng/mL), with or without anti- 
CXCL10 Abs (40 µg/mL), or with IL30sup, with or without anti- CXCL10 Abs (40 µg/mL). ANOVA: p<0.0001. *p<0.01, Tukey 
HSD test compared with CTRL, rmIL30  + anti- CXCL10 Abs and IL30sup. **p<0.01, Tukey HSD test compared with CTRL, 
rmIL30, rmIL30  + anti- CXCL10 Abs and IL30sup + anti- CXCL10 Abs. ***p<0.01, Tukey HSD test compared with CTRL. (E) 
Cytofluorimetric analyses of IL23R expression in mBCSCs and mBC cells. Red lines: isotype control. Blue lines: specific Abs. 
Experiments were performed in triplicate. (F) Cytofluorimetric analyses of CXCR3 expression in hBCSCs. Red lines: isotype 
control. Blue lines: specific Abs. Experiments were performed in triplicate. (G) Expression of CXCR3 isoforms in hBCSCs, as 
determined by RT- PCR. CXCR3A: 111 bp; CXCR3B: 79 bp; CXCR3- alt: 135 bp. (H, I) Relative expression ±SD of mRNA of the 
three CXCR3 isoforms in BCSC- 608 (H) and in BCSC- 105 (I). (J) Cytofluorimetric analyses of IL23R expression in hBCSCs. 
Red line: isotype control. Blue lines: specific Abs. Experiments were performed in triplicate. (K) MTT assay of BCSC- 608 after 
48 hours of treatment with rCXCL10 at concentration of 5–100 ng/mL. ANOVA: p=0.00001. *p<0.01, Tukey HSD test compared 
with 0 ng/mL. (L) MTT assay of BCSC- 105 after 48 hours of treatment with rCXCL10 at concentrations of 5–100 ng/mL. ANOVA: 
p=0.00002. *p<0.01, Tukey HSD test compared with 0 ng/mL. (M) MTT assay of BCSC- 608 after 48 hours of treatment with rIL23 
at concentrations of 5–100 ng/mL. ANOVA: p=0.0000002. *p<0.01, Tukey HSD test compared with 0 ng/mL. (N) MTT assay of 
BCSC- 105 after 48 hours of treatment with rhIL23 at concentrations of 5–100 ng/mL. ANOVA: p=0.0028. *p<0.05, Tukey HSD 
test compared with 0 ng/mL. (O, P) Sphere- forming capacity, evaluated by ELDA, of (O) BCSC- 608 (*p<0.0001, χ2 test versus 
CTRL) and (P) BCSC- 105 (*p=0.0029, χ2 test versus CTRL) cells, after 8 days of treatment with 50 ng/mL of rCXCL10. (Q, R) 
Sphere- forming capacity, evaluated by ELDA, of (Q) BCSC- 608 (*p<0.0001, χ2 test versus CTRL) and (R) BCSC- 105 (*p=0.0044, 
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Figure 4 IL30- dependent production of CXCL10 and IL23 in breast cancer stem cells (BCSCs) and related autocrine loops. 
(A) Confocal microscopy images of IL30 (green) and CXCL10 (red) in EV and IL30 gene transfected BCSC- 608 cells. DAPI: 
DNA- stained nuclei. Magnification EV- BCSC- 608: ×630; IL30- BCSC- 608: ×1000. Scale bars EV- BCSC- 608: 6 µm; IL30- 
BCSC- 608: 3 µm. (B) Confocal microscopy images of IL30 (green) and IL23 (red) in EV and IL30 gene transfected BCSC- 608 
cells. DAPI: DNA- stained nuclei. Magnification EV- BCSC- 608: ×630; IL30- BCSC- 608: ×1000. Scale bars EV- BCSC- 608: 6 µm; 
IL30- BCSC- 608: 3 µm. (C) Confocal microscopy images of IL30 (green) and CXCL10 (red) in EV and IL30 gene transfected 
BCSC- 105 cells. DAPI: DNA- stained nuclei. Magnification: ×630. Scale bars: 6 µm. (D) MTT assay of IL30- overexpressing (light 
blue bars) or wild- type (CTRL, orange bars) BCSC- 608 cells, treated with different concentrations of anti- CXCL10 Abs. ANOVA: 
p<0.0001. *p<0.01, Tukey HSD test compared with untreated CTRL cells. **p<0.05 Tukey HSD test compared with untreated 
CTRL and IL30- overexpressing cells. ***p<0.01 Tukey HSD test compared with untreated IL30- overexpressing cells. Results 
obtained from EV- transfected cells were comparable with those from CTRL cells. (E) MTT assay of IL30- overexpressing (light 
blue bars) or wild- type (CTRL, orange bars) BCSC- 608 cells, treated with different concentrations of anti- IL23 Abs. ANOVA: 
p<0.01. *p<0.01, Tukey HSD test compared with untreated CTRL cells. **p<0.05 Tukey HSD test compared with untreated IL30- 
overexpressing cells. Results obtained from EV- transfected cells were comparable with those from CTRL cells. (F) MTT assay 
of IL30- overexpressing (light blue bars) or wild- type (CTRL, orange bars) BCSC- 608 cells, treated with different concentrations 
of anti- CXCL10 and anti- IL23 Abs. ANOVA: p<0.0001. *p<0.01, Tukey HSD test compared with untreated CTRL cells. **p<0.01 
Tukey HSD test compared with untreated CTRL and IL30- overexpressing cells. ***p<0.01 Tukey HSD test compared with 
untreated IL30- overexpressing cells. Results obtained from EV- transfected cells were comparable with those from CTRL cells. 
(G) MTT assay of IL30- overexpressing (light green bars) or wild- type (CTRL, yellow bars) BCSC- 105 cells, treated with different 
concentrations of anti- CXCL10 Abs. ANOVA: p<0.0001. *p<0.01, Tukey HSD test compared with untreated CTRL cells. **p<0.05 
Tukey HSD test compared with untreated CTRL and IL30- overexpressing cells. ***p<0.05 Tukey HSD test compared with 
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volume (MTV) significantly higher than control tumors 
(MTV of IL30mBCSC tumors: 671.66±158.95 mm3; MTV 
of EVmBCSC tumors: 160.31±56.34 mm3; MTV of mBCSC 
tumors: 164.50±58.90 mm3; ANOVA: p<0.0001; Tukey 
HSD test: p<0.01; figure 5A).
The survival of mice bearing IL30- overexpressing 
tumors was significantly lower (log- rank test: p<0.0001) 
than that of control tumor- bearing mice (figure 5B). 
Both EV- derived and mBCSC- derived tumors recapit-
ulated the histologic and immunophenotypic features 
(E- cadherin+, CK8+, CK14+, ER− and PR−, HER2low) of the 
BC from which the cells were isolated (online supple-
mental figure S5).21 33 By contrast, tumors developed after 
implantation of IL30mBCSCs were poorly differentiated 
(figure 5C a,b), and expressed IL30 (figure 5C, c,d) and 
stemness genes, especially Myc (which is upregulated 
by IL30, both in vitro, figure 2G, and in vivo, figure 5D, 
a,b; IL30mBCSC tumors, 81.56%±7.38%; EVmBCSC 
tumors, 49.20%±7.15%; mBCSC tumors, 46.6%±4.55%; 
ANOVA: p<0.0001; Tukey HSD test: p<0.01, IL30mBCSC 
tumors versus EVmBCSC and mBCSC tumors) and Klf4 
(figure 5D c,d; IL30mBCSC tumors, 76.33%±6.67%; 
EVmBCSC tumors, 53.67%±8.49%; mBCSC tumors, 
51.89%±3.52%; ANOVA: p<0.001; Tukey HSD test: 
p<0.01, IL30mBCSC tumors versus EVmBCSC and 
mBCSC tumors; figure 5E; 10.32 times upregulation 
of Klf4 in vitro), which, along with Snai2 (2.48 times), 
Zeb1 (3.61 times) and Zeb2 (3.01 times), were upregu-
lated also in mBCSCs treated with rIL30 (figure 5E). 
IL30- overexpressing tumors were highly proliferating 
(IL30mBCSC tumors, 83.00%±6.56%; EVmBCSC tumors, 
48.78%±4.84%; mBCSC tumors, 49.00%±3.20%; ANOVA: 
p<0.0001; Tukey HSD test: p<0.01, IL30mBCSC tumors 
versus EVmBCSC and mBCSC tumors) and well vascular-
ized (MVD: IL30mBCSC tumors, 14.13±2.64; EVmBCSC 
tumors, 7.11±1.76; mBCSC tumors, 6.44±1.51; ANOVA: 
p<0.0001; Tukey HSD test: p<0.01, IL30mBCSC tumors 
versus EVmBCSC and mBCSC tumors; figure 5C, e–h). 
Genes that were the most upregulated by IL30 in BCSCs, 
including Cxcl10 and IL23, were strongly expressed also 
by IL30- overexpressing tumors (figure 5C, i–l), which were 
heavily infiltrated by F4/80+ macrophages, CD11b+Gr- 1+ 
myeloid derived cells (MDC), Ly- 6G+ granulocytes, 
Foxp3+ T regulatory (Tregs) cells and NKp46+RORγt+ 
type 3 innate lymphoid cells (ILC3) (figure 5F,G). This 
immune cell population mostly co- localised with intratu-
moral expression of IL22 and IL17 (figure 5H).
IL30 overproduction by BCSCs promotes their survival in the 
bloodstream and seeding in the lung, increasing the incidence 
of metastases, which recapitulate the immune contexture of 
the primary tumors
The most common sites of metastasis for BC are the bones 
and lungs.34 IL30 has proven to boost tumor progression4 
12 18 and this article and to favor bone marrow and lung coloni-
zation.4 In the present model of BCSCs, in which the lung 
is the main site of metastasis,19 to investigate the effects 
of IL30 on the different metastatic phases, we compared 
spontaneous versus experimental metastasis.
Although the number of mice which developed 
metastases was not significantly different between mice 
bearing EV, or wild- type, tumors and mice bearing IL30- 
overexpressing tumors (18/30 versus 24/30), the latter 
developed an average number of lung metastases (mets) 
that was significantly higher than in control tumor- bearing 
mice (average number of 9 mets/mouse developed from 
IL30mBCSC tumors versus 2 mets/mouse from mBCSC 
and EVmBCSC tumors; ANOVA: p<0.0001; Tukey HSD 
test: p<0.01; figure 6A). The number of metastases per 
mouse did not correlate with the tumor size, as deter-
mined by Pearson’s correlation coefficient (r=0.0137).
Inflammatory microenvironment and immune contex-
ture of lung metastasis (figure 6B, a,b) were consistent 
with the immunopathologic features of the primary 
tumors. Indeed, metastasis which developed from IL30- 
overexpressing tumors showed higher proliferation index 
(mean percentage ±SD of PCNA- positive cells/number of 
total cells per field: IL30mBCSC tumors, 77.33%±7.99%) 
than metastasis from control tumors (EVmBCSC tumors, 
36.75%±6.30%; mBCSC tumors, 37.25%±7.92%; ANOVA: 
p<0.0001; Tukey HSD test: p<0.01 versus both controls) 
(figure 6B, c,d) and a prominent expression of CXCL10 
and IL23 (figure 6B, e–h). Metastases developed from 
IL30- overexpressing tumors were heavily infiltrated by 
macrophages (11.57±3.69 versus EVmBCSC, 3.00±1.26, 
and mBCSC, 3.83±1.47), Foxp3+ Tregs (9.44±3.28 versus 
EVmBCSC: 2.11±1.17 and mBCSC: 3.00±1.41) (figure 6B, 
i,j) and NKp46+RORγt+ ILC3 (12.67±4.18 versus EVmBCSC, 
3.70±1.42, and mBCSC, 4.10±2.13) (ANOVA: p<0.0001; 
Tukey HSD test: p<0.01 versus both controls) (figure 6B, 
k,l, and magnification in figure 6C a), which expanded 
under the pleura, and bronchial mucosa (figure 6C, b). 
Experimental metastasis experiments revealed that 100% 
(30/30) of mice intravenously injected with IL30mBCSCs 
developed lung metastasis (average number of 1.7 metas-
tasis/mouse) versus only 27% (8/30) of mice injected 
with EVmBCSCs, and 33% (10/30) of mice injected with 
mBCSCs (average number of 1.5 metastasis/mouse) 
(Fisher’s exact test, p<0.0001; figure 6D). The immuno-
pathological characteristics were comparable with those 
found in spontaneous metastases. These findings suggest 
that IL30 produced by BCSCs supports their survival in 
the bloodstream and favors their extravasation and prolif-
eration in the lungs.
Expression of IL30 in clinical BC samples correlates with that 
of CXCL10 and IL23, which are prevalent in TNBC
To evaluate whether the induction of CXCL10 and IL23, 
by IL30, in BCSCs may have clinical–pathological impli-
cations, we analysed RNA- sequencing data of tumor 
samples obtained from 1084 patients with BC, included 
in the “Breast Invasive Carcinoma TCGA PanCancer collec-
tion” published by the Cancer Genome ATLAS (TCGA) 
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Figure 5 Growth rate and immune contexture of tumors developed after orthotopic implantation of IL30- overexpressing 
mBCSCs in syngeneic host. (A) Mean volume of tumors developed after orthotopic implantation of IL30mBCSCs, EVmBCSCs 
or wild- type mBCSCs. ANOVA, p<0.0001; Tukey HSD test, p<0.01 versus both controls. (B) Kaplan- Meier survival curves 
of mice bearing tumors developed after orthotopic implantation of IL30mBCSCs, EVmBCSCs or mBCSCs. Log- rank test: 
p=0.000024. (C) H&E- stained sections (a, b) and immunopathological features (c–l) of tumors developed after orthotopic 
implantation of EVmBCSCs or IL30mBCSCs in syngeneic mice. Histology and immunopathology of tumors induced by 
mBCSCs were comparable with those induced by EVmBCSCs. Magnification: ×400. Scale bars: 20 µm. (D) Expression of MYC 
and KLF4 in tumors induced by EV (a, c) and Il30 gene transfected (b, d) mBCSCs. Magnification: ×400. Scale bars: 20 µm. 
(E) Fold differences of mRNAs of stemness- related genes between IL30mBCSCs and EVmBCSCs. Results obtained from 
EVmBCSCs are comparable with those from wild- type CTRL cells. Pooled results±SD are from two experiments performed 
in duplicate. A significant threshold of 2- fold change in gene expression corresponded to p<0.001. (F) Automated immune 
cell count in tumors developed after implantation of IL30mBCSCs, EVmBCSCs (EV) or mBCSCs (CTRL) in syngeneic mice, 
assessed by immunohistochemistry, as described in Methods section. ANOVA: p<0.001. *p<0.01, Tukey HSD test compared 
with EV and CTRL. (G) Immune cell contexture of tumors developed after orthotopic implantation of IL30mBCSCs reveals a 
greater content of F4/80+ macrophages (a, b), CD11b+ cells (c, d; red stained in the inset) mostly co- expressing Gr- 1 (brown 
stained in the inset), Ly- 6G+ granulocytes (e, f) and Foxp3+ Tregs (g, h) than control tumors. Magnification: ×400; inset in d: 
×630. Scale bars: 20 µm; inset in d: 10 µm. (H) Double staining with anti- RORγt (brown) and anti- NKp46 (red) Abs revealed that, 
unlike control tumors (a), tumors induced by IL30mBCSCs (b) were heavily infiltrated by NKp46+ cells endowed with RORγt+ 
nuclei, indicative of ILC3. Intratumoral expression of IL22 (c, d) and IL17 (e, f) was localized in the areas infiltrated by ILC3. 
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IL30mRNA was associated with Triple- Negative BC,18 the 
subtype with the highest CD133+ stem cell content.19 35
Since TNBC is the most represented BC subtype (26 
out of 75 cases) in the database developed by Waddell et 
al,36 included in the Oncomine Platform (https://www. 
oncomine. org), we performed an outlier analysis of gene 
expression data from this sample collection, using the 
Cancer Outlier Profile Analysis (COPA) algorithm, which 
revealed that IL30 expression ranked beyond the 95th 
percentile and, therefore, it was in the top 5% (COPA 
score=16.727) of the most expressed genes.
Profiling of tumor infiltrating immune cells, by using 
CIBERSORTx computational method (http:// cibersort. 
stanford. edu/), revealed that the median percentage of 
both naïve and memory resting CD4+ T cells, γδ T cells 
and resting dendritic cells (DCs) was significantly lower in 
IL30 highly expressing (IL30high) BC samples (calculated 
after the exclusion of cases that also overexpressed EBI3, 
Z- score ≥1, to avoid effects due to IL27) versus IL30 low 
expressing (IL30low) BCs (online supplemental table S6). 
Profiling of immune exhaustion markers, which include 
immune checkpoint molecules (online supplemental 
Figure 6 Immune microenvironment of lung metastasis induced by IL30- overexpressing mBCSCs and expression of IL30- 
induced secondary mediators, CXCL10 and IL23, in human breast cancers (BCs). (A) Average number of lung metastasis per 
mouse spontaneously developed from tumors induced by IL30mBCSCs, EVmBCSCs or wild- type mBCSCs. ANOVA: p<0.0001; 
Tukey HSD test: p<0.01 versus both controls. (B) Histopathological features and immune contexture of lung metastasis 
spontaneously developed from tumors induced by IL30mBCSC and EVmBCSC implantation in syngeneic mice. Magnification: 
a, b, k, l, ×200; c–j: ×400. Scale bars a, b, k, l: 30 µm; c–j: 20 µm. (C) In lung metastasis developed from IL30- overexpressing 
tumors, ILC3 infiltrate extends under the pleura (a, detail of figure B, l) and bronchial mucosa (b). Magnification a: ×630; b: ×200. 
Scale bars a: 10 µm; B: 30 µm. (D) Percentage of mice which developed lung metastasis 40 days after intravenous injection of 
IL30mBCSCs, EVmBCSCs or mBCSCs. *Fisher’s exact test, p<0.0001 versus both controls. (E) Immunohistochemical analysis 
of LAG3 expression in tumors developed after orthotopic implantation of EV- mBCSCs (a) and IL30mBCSCs (b) in syngeneic 
mice. Magnification: ×400. Scale bars: 20 µm. (F) CXCL10mRNA expression in human BC subtypes from the PanCancer cohort. 
The histogram represents the percentage of CXCL10mRNA overexpressing cases (Z- score >2) out of the total number of cases 
for each BC subtype. (G) Distribution of CXCL10+ BCs by molecular subtypes, represented as percentage of the total number 
of BC expressing CXCL10mRNA. (H) IL23mRNA expression in human BC subtypes from the PanCancer cohort. The histogram 
represents the percentage of IL23 overexpressing cases (Z- score >2) out of the total number of cases for each BC subtype. (I) 
Distribution of IL23+ BCs by molecular subtypes, represented as percentage of the total number of BC expressing IL23mRNA. 
(J) Double immunostaining of TNBC tissues showing IL30 (red) co- localization with CD133+ (brown) cancer cells. Magnification: 
×630. Scale bar: 10 µm. (K) Double immunostaining of TNBC tissues showing CXCL10 (red) co- localization with CD133+ 
(brown) cancer cells. Magnification: ×1000. Scale bar: 6 µm. (L) Double immunostaining of TNBC tissues showing IL23 (red) co- 
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table S7), performed to test the functional status of 
tumor- infiltrating immune cells, revealed a significantly 
higher expression of LAG3 in M1 macrophages infil-
trating IL30high BCs (1.67- fold), compared with the corre-
sponding cell population in IL30low BCs (Student’s t- test: 
p=0.0121). This finding is consistent with the upregula-
tion of LAG3 by IL30 treatment in mBCSCs (figure 2G) 
and mTNBC cells,18 and with its production, by cancer 
and infiltrating immune cells in IL30- overexpressing 
murine tumors (figure 6E, a,b).
Analysis of gene expression profiles, provided by the 
PanCancer dataset, also revealed a significant association 
between the expression of CXCL10mRNA and TNBC 
(Fisher’s exact test, p<0.05 versus HER2+, Normal- like, 
Luminal A and Luminal B) (figure 6F). CXCL10mRNA 
expression was detected in 89% of TN, 7% of HER2+ and 
4% of Luminal B (figure 6G). A significant association was 
also found between the expression of IL23AmRNA and 
TNBC (Fisher’s exact test, p<0.01 versus HER2+, Luminal 
A and Luminal B) (figure 6H). IL23AmRNA expression 
involved 65% of TN, 7% of HER2+, 20% of Luminal A, 
5% of Normal- like, and 3% of Luminal B (figure 6I).
Bioinformatic analyses revealed a positive correlation, 
by Spearman’s rank correlation coefficient, between the 
expression of IL30 and that of CXCL10 (ρ=0.493), and 
IL23A (ρ=0.313). Furthermore, the expression of CXCL10 
was positively correlated to that of IL23A (ρ=0.421). Immu-
nostaining confirms, in TNBC samples, the production 
of IL30 in CD133+ BCSCs (figure 6J) and the frequent 
co- expression of CXCL10 (58.34%±4.62%, mean±SD 
of CXCL10- positive cells/total number of CD133+IL30+ 
cells per field) and IL23 (51.28%±8.22%, mean±SD of 
IL23- positive cells/total number of CD133+IL30+ cells 
per field) (Student’s t- test: p<0.00001) (figure 6K,L, and 
online supplemental table S8), thereby supporting the 
finding of the role of IL30- driven cytokine circuits in 
BCSC behavior.
DISCUSSION
Despite therapeutic advancements, BC remains a 
dreadful disease, estimated to cause 655,690 deaths 
worldwide this year.1 Leading causes of BC‐related deaths 
are tumor recurrence and metastasis, which are driven 
by self- renewing and multipotent BCSCs, highly resistant 
to current therapies.2 3 The balance between quiescence, 
proliferation and differentiation of CSCs is regulated by 
paracrine, autocrine and contact- dependent signals.37 
Here, we provide evidence that IL30 affects directly, and 
via second- level mediators, BCSC behavior and immune 
contexture. Cancer SCs isolated from human BCs are 
unable to release IL30 or IL27, but constitutively express 
IL30 as a membrane- anchored glycoprotein and alter-
ation of its expression levels, by enforced overexpression 
or silencing, dramatically increases, or inhibits, respec-
tively, their viability and self- renewal efficiency, and 
subverts their immunity gene expression profile. The 
lack of IL30 in the supernatant of hIL30 gene transfected 
hBCSCs is consistent with data reported by Pflanz and 
coworkers,6 who failed to detect hIL30 protein in the 
supernatant of hHEK293 cells, after transfection with 
hp28, whereas transfection with the murine counterpart 
resulted in protein secretion.
Since alteration of IL30 protein levels, by gene trans-
fection, localized neither in the cytoplasm nor in the 
supernatant, but in the plasma membrane, the functional 
outcomes are likely due to juxtacrine signals activated 
by a membrane- bound bioactive IL30. The blockade of 
these contact- dependent signals, by anti- IL30 neutralizing 
Abs, hinders proliferation and self- renewal of hBCSCs, 
suggesting IL30’s ability to control the maintenance and 
expansion of the CSC compartment. Therefore, IL30 
enters the group of human membrane- anchored cyto-
kines, which includes IL1α,38 IL15,39 M- CSF,40 Flt3 ligand,41 
TNFα,42 LTα,43 Fractalkine/CX3CL1,44 TGFβ45 and IFNγ,46 
that have demonstrated biological effects via the juxtacrine 
route, under physiological conditions. Signaling through 
cell–cell contact, IL30 overexpressed by hBCSCs triggers a 
storm of inflammatory mediators, including IL1β, TNFα, 
CCL4, CXCL8, CXCL10 and, especially, CSF2/GM- CSF, 
CXCL1, IL23A and CXCL10. By contrast, silencing of 
the IL30 gene downregulates tumor- promoting factors, 
such as CCL28, CCL5, CCR2, CXCR2, CXCR4, NOS2, 
PDL2, PTGS2 and, especially, IL1β and STAT3, which 
is functional to IL30 signaling in TNBC cells.15 TNBC 
has the highest BCSC content19 and the most frequent 
expression of IL30.15 Targeting IL30 in the host environ-
ment has proven effective against TNBC progression.18 
Analyses of TNBCs developed in IL30 knocked out mice 
after implantation of IL30 responsive or unresponsive (ie, 
with or without IL30R) TNBC cells provided an opportu-
nity to analyze the effects of IL30 on the tumor immune 
contexture.5 18 Regardless of the induction of CXCL10, 
IL23 or other mediators in tumor cells, endogenous IL30 
prevents the intratumoral recruitment of CD8+ T, CD4+ T 
and NKp46+ cells, along with IFNγ production, and favors 
the influx of immunosuppressive IDO+ MDCs, macro-
phages and Tregs. By contrast, the lack of endogenous 
IL30 prevents the expansion of IL10+CD4+CD25+Foxp3+ 
Tregs, during tumor growth, whereas it favors intratumoral 
T- cell infiltration, mainly of CD4+ T lymphocytes, and cyto-
toxic functions. These data could explain why, despite IL30 
induces in tumor cells CXCL10, which has been reported to 
recruit activated CXCR3+ Th1 cells,47 IL30- overexpressing 
tumors lack enrichment in T lymphocytes.
Unlike the human counterpart, mIL30 is efficiently 
released by Il30 gene transfected mBCSCs, as a soluble 
mediator. Similarly to the human cytokine, mIL30 
promotes the proliferation and self- renewal of mBCSCs, 
and fosters their expression of oncogenes Bcl2l1 and Myc, 
and a range of immune regulatory factors, such as Ccl20, 
Csf3, Cxcl12 and, particularly, Ptgs2, Vegfa, Cxcl10 and 
Il23, most of which are also induced by IL30 in murine 
and human TNBC cells.15 18
Human and murine IL30- associated immune gene 
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and IL23. Both molecules are secreted by BCSCs in 
response to IL30 and mediate most of the IL30- dependent 
proliferation and self- renewal, which are suppressed by 
their selective blockade, suggesting novel autocrine loops 
that foster CSCs and can be disrupted by targeting IL30 
signaling. In hBCSCs, IL30 overexpression also promotes 
the release of CSF2 and CXCL1. Despite being used 
for its immune adjuvant function,48 when produced by 
BC, CSF2 has revealed immunosuppressive and tumor- 
promoting effects, and positive correlation with a worst 
clinical outcome.49 50 CXCL1 has been recently demon-
strated to sustain proliferation and self- renewal of BCSCs, 
and to regulate their transcriptional profile, by promoting 
tumor progression and immune escape programs.51
Orthotopic implantation, in immune- competent host, 
of BCSCs engineered to release IL30 provides novel 
insight into the tumor- promoting functions of this cyto-
kine. IL30 overexpression by mBCSCs accelerates tumor 
growth and reduces host survival, in association with 
an increased cancer proliferation, vascularization and 
expression of stemness genes, including MYC and KLF4, 
which play a key role in the maintenance of BCSCs.16 52 
CXCL10 and IL23 were produced by IL30- overexpressing 
tumors, which were heavily infiltrated by macrophages, 
MDCs, granulocytes, Tregs and ILC3. In addition to 
CXCL10 and IL23, a wide range of IL30- induced pro- 
inflammatory factors could account for this immune 
cell context, in particular, CSF3/G- CSF, IL1α, VEGF and 
PTGS2, which are the most upregulated.
G- CSF can modulate the tumor microenvironment, by 
promoting angiogenesis and granulocyte, macrophage 
and MDSC recruitment.53 IL1α recruits neutrophils,54 
favors angiogenesis,55 and promotes the expansion of 
BCSCs and metastasis.56 57 Tumor hyperproduction of 
VEGFA fosters endothelial cell proliferation and vascular 
leakage favoring leukocyte extravasation, but also inhibits 
functional maturation of DC58 and promotes immature 
myeloid cell recruitment.58
High levels of COX2 and PGE2 by tumor cells directly 
recruit Tregs and contribute to CD8+ T lymphocyte apop-
tosis in murine BC.59
CXCL10 exhibits pleiotropic function in tumor biology 
since its interaction with CXCR3- A leads to tumor cells 
survival and proliferation, whereas interaction with 
CXCR3- B mediates anti- proliferative, pro- apoptotic and 
angiostatic effects.60 In BC, overexpression of CXCR3- B 
has demonstrated to enhance the sphere- forming poten-
tial of CSC and to amplify their compartment, which is 
depleted by CXCR3- B silencing.61 Here, we demonstrated 
that mBCSCs are endowed with CXCR3, and hBCSCs 
express isoforms A and B, and that both cell lines respond 
to CXCL10 by increasing their proliferation and sphere- 
forming ability. Originally identified as a chemoattractant 
of CXCR3+ leukocytes, including macrophages, dendritic 
and NK cells and activated T lymphocytes,62 CXCL10 has 
been shown to also recruit Tregs63 and increase transcrip-
tion of T- bet and RORγt, leading to the polarization of Tr1 
and Th17 from naïve T cells.64 Thereby, CXCL10 released 
by IL30- stimulated BCSCs may contribute in shaping 
their immune contexture, which is enriched in Tregs and 
NKp46+RORγt+ ILC3. ILC3 co- localizes with IL22 and 
IL17, which fuel an immunosuppressive environment.65 66 
Produced by IL30- overexpressing tumors, IL23 can lead 
to the expansion of ILC367 and enable their expression 
of IL17 and IL22.67 Although their role in cancer is yet to 
be clarified, ILC3 promote LN metastasis in BC,68 and in 
NSCLC their percentage has been associated with IL23 
expression in tumor cells and with short patient survival.69 
Expression of IL23p19 is frequent in human tumors and 
it has been demonstrated to boost angiogenesis and 
innate inflammatory influx, while inhibiting CD8+ T cell 
infiltrate, thus promoting tumor growth.70 In patients 
with BC, serum level of IL23 correlates with shorter 
overall survival and its overexpression with BCSC prolif-
eration.71 72 Hyperproliferation, along with the consider-
able production of IL23 and CXCL10, observed in the 
context of murine IL30- positive tumors, was also found 
in spontaneous and experimental metastasis induced 
by IL30- overexpressing BCSCs. Although the metastatic 
propensity of mBCSCs21 does not allow to detect a differ-
ence in the number of mice which develop metastasis, 
between those bearing IL30- negative and IL30- positive 
tumors, the latter develop more metastasis per mouse and 
have reduced survival. The greater number of metastatic 
cases among mice receiving intravenous inoculation of 
IL30- overexpressing BCSCs versus control cells indicates 
that IL30 supports CSC survival in the bloodstream, 
extravasation and engraftment in the lung, where the 
immune contexture mirrors that of spontaneous metas-
tasis and their primary tumors. Bioinformatic evidence of 
a correlation between the expression of IL30 and that of 
CXCL10 and IL23 in human BC tissues, and their preva-
lence in TNBCs, in which IL30+ BCSCs frequently co- ex-
press CXCL10 and IL23, supports the translational value 
of our finding and emphasizes the pathobiological role 
of the IL30- driven inflammatory cascade in BC behavior. 
Since IL30 has been found in the top 5% of the most 
expressed genes in the TN enriched BC collection,36 it 
can be argued that the IL30- driven tumor- promoting 
circuit may be of relevance in the pathobiology and evolu-
tion of the most aggressive forms of BC.
The CIBERSORTx algorithm provided new informa-
tion on the immune profile associated with IL30 over-
expression in the BC microenvironment, by revealing 
a lower content in γδ T cells, and a defective infiltrate 
of naïve and memory resting CD4+ T cells and DCs, in 
IL30high compared with IL30low BCs.
Intratumoral γδ T cells emerged as the most signifi-
cant favorable cancer- wide prognostic population73 and 
have been associated with remission in TNBC subtype.74 
However, their role is controversial,75 76 possibly due to 
the heterogeneity of the BC microenvironment that, 
depending on the immune contexture, oncogenic 
signaling and cytokine milieu, can polarize γδ T cells 
toward an anti- tumoral or pro- tumoral phenotype.77 78 The 
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effector γδ T- cell subsets endowed with anti- tumor activity 
is yet to be investigated, as well as the biological and prog-
nostic value of its naïve and memory resting CD4+ T and 
DC infiltrate.
On the other hand, expression of LAG3 in M1 macro-
phages, which has recently been observed also in diffuse 
large B- cell lymphoma,79 characterizes IL30high BCs, and 
corroborates our experimental findings, 18 and this paper 
providing evidence of the functional immune exhaustion 
associated with IL30- rich microenvironment.
In addition to providing new clues, through biosta-
tistical investigations, of the tumor- promoting activity 
of IL30, our study demonstrates that BCSCs express 
membrane- bound IL30, which sustains their expansion 
directly and via second- level cytokines, mainly, CXCL10 
and IL23. These immune regulatory factors mediate 
autocrine proliferative and self- renewal loops, but also 
contribute, together with the other second- level medi-
ators, to the IL30- associated immune microenviron-
ment. Targeting the IL30 pathway is a valuable strategy 
to restrain the BCSC compartment and to counteract 
immune suppression and BC progression.
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